» Articles » PMID: 39570045

Effect of Metronidazole on Concentrations of Vaginal Bacteria Associated with Risk of HIV Acquisition

Overview
Journal mBio
Specialty Microbiology
Date 2024 Nov 21
PMID 39570045
Authors
Affiliations
Soon will be listed here.
Abstract

Several bacterial vaginosis (BV)-associated bacteria have been associated with elevated risk of human immunodeficiency virus (HIV) acquisition; however, susceptibility of these bacteria to antibiotics is poorly understood. Vaginal samples were collected from 22 persons daily for 2 weeks following BV diagnosis. Metronidazole treatment was prescribed for 5-7 days. Changes in bacterial concentrations were measured with taxon-specific 16S rRNA gene quantitative PCR (qPCR) assays. A culture-based antimicrobial assay confirmed presence of antibiotics in vaginal swab samples. Bacterial DNA concentrations decreased during antibiotic administration for all 13 bacterial taxa tested. Comparison of bacterial DNA concentrations in samples before administration of antibiotics to samples taken on the last day of antimicrobial assay-confirmed antibiotic presence showed a 2.25-4.78 log10-fold decrease across all taxa. Concentrations were frequently reduced to the qPCR assay's limit of detection, suggesting eradication of bacteria. Mean clearance time varied across taxa (1.2-7.9 days), with several bacteria (e.g., spp., Vaginal TM7, and -like sp.) taking >7 days to suppress. Metronidazole reduces quantities of bacterial taxa associated with increased HIV acquisition risk.IMPORTANCEHuman immunodeficiency virus (HIV) transmission through sex remains a major public health challenge despite efforts at risk reduction and use of anti-retroviral pre-exposure prophylaxis. Many bacterial vaginosis (BV)-associated vaginal bacteria have been associated with increased HIV infection risk among women. If these bacteria help mediate HIV infection risk, then eradication of these bacteria is one potential strategy to reduce this risk. However, the best approach to eradicate HIV-high risk bacteria from the vagina is not known. We analyzed vaginal swabs collected daily from women with BV to determine the impact of metronidazole treatment on 13 vaginal bacterial taxa linked to elevated risk of HIV infection through use of taxon-directed quantitative PCR assays. We conclude that eradication of high-risk vaginal bacteria using metronidazole is one promising avenue for reducing HIV acquisition risk, and we provide evidence that a 5-7-day treatment course may not be sufficient to suppress all bacteria.

Citing Articles

Simultaneous determination of five nitroimidazole antimicrobials in pharmaceuticals using HPLC-ESM and QAMS methods.

Fang B, Jiang D, Wang S, Chen F BMC Chem. 2025; 19(1):40.

PMID: 39953570 PMC: 11829564. DOI: 10.1186/s13065-025-01409-1.

References
1.
Srinivasan S, Richardson B, Wallis J, Fiedler T, Strenk S, Hoffman N . Vaginal Bacteria and Proinflammatory Host Immune Mediators as Biomarkers of Human Immunodeficiency Virus Acquisition Risk Among African Women. J Infect Dis. 2024; 230(6):1444-1455. PMC: 11646615. DOI: 10.1093/infdis/jiae406. View

2.
Srinivasan S, Hoffman N, Morgan M, Matsen F, Fiedler T, Hall R . Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One. 2012; 7(6):e37818. PMC: 3377712. DOI: 10.1371/journal.pone.0037818. View

3.
Schwebke J, Desmond R . A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2006; 44(2):213-9. DOI: 10.1086/509577. View

4.
Fredricks D, Fiedler T, Thomas K, Mitchell C, Marrazzo J . Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol. 2009; 47(3):721-6. PMC: 2650913. DOI: 10.1128/JCM.01384-08. View

5.
Baisley K, Changalucha J, Weiss H, Mugeye K, Everett D, Hambleton I . Bacterial vaginosis in female facility workers in north-western Tanzania: prevalence and risk factors. Sex Transm Infect. 2009; 85(5):370-5. PMC: 2709714. DOI: 10.1136/sti.2008.035543. View